Pursuant to the Danish Securities Trading Act, Section 28(a), LifeCycle Pharma A/S (OMX: LCP) is required on a daily basis, to make public transactions in LifeCycle Pharma shares and related securities by persons discharging managerial responsibilities and persons / companies closely associated with these.
| Name | Â | Karin J. Hamberg |
| Reason for reporting | Â | EVP & CMO |
| Issuer and ID code/ISIN | Â | LifeCycle Pharma A/S / DK0060048148 |
| Type of transaction | Â | Purchase of shares |
| Date of transaction | Â | March 6, 2009 |
| Relevant market | Â | NASDAQ OMX Copenhagen |
| Number of traded securities | Â | 5,000 |
| Market value | Â | DKK 50,000 |
About LifeCycle Pharma A/S (LCP)
Based in Hørsholm, Denmark, with an office in New York, LCP is an emerging specialty pharmaceutical company. Clinical development is the core of LCP’s effort to develop a product portfolio which includes products for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. As a fully integrated company, LCP adapts new technologies on a fast commercial timetable. LCP’s unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability - at low-scale up costs - not only for a broad spectrum of drugs already on the market but also for new chemical entities. LCP has a cholesterol-lowering product, Fenoglide™, currently on the U.S. market and a diversified near- and medium-term pipeline with four product candidates in clinical trials and a number of projects in preclinical development. LCP is listed on NASDAQ OMX Copenhagen under the trading symbol (OMX: LCP).
For further information, please visit www.lcpharma.com
Contacts:
LifeCycle Pharma A/S
Head of Investor Relations
Peter Schøtt
Knudsen, + 45 2055 3817
PSK@lcpharma.com
